Survey: Nearly a third of adults say they are very unlikely to get their children vaccinated for COVID-19

In a press release, Pfizer and BioNTech stated, “…results from a Phase 2/3 trial show a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age."

Related Keywords

United States ,American ,Rachel Brewer ,Ian Kaminsky ,American Academy Of Pediatrics ,Pfizer ,American Academy ,Covi 19 Pandemic ,Child Covid 19 Vaccine ,Vaccinating Children ,Vaccinations Across The Nation ,